← Back to Clinical Trials
Recruiting NCT07602010

NCT07602010 Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07602010
Status Recruiting
Phase
Sponsor Oslo University Hospital
Condition Bladder Cancer
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2026-04-22
Primary Completion 2028-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2026-04-22 with a primary completion date of 2028-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective diagnostic accuracy study compares computed tomography (CT) and multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) for local staging of newly diagnosed bladder cancer. All participants undergo both imaging modalities prior to transurethral resection of the bladder tumor (TURBT) or cystectomy. Histopathology serves as the reference standard.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Newly diagnosed bladder cancer on cystoscopy * Planned TURBT or cystectomy within 6 weeks * Eligible for both CT and MRI within 6 weeks * Written informed consent provided Exclusion Criteria: * Contraindications to MRI or iodinated contrast media * Prior treatment for bladder cancer * Pregnancy * Non-malignant bladder lesions * Tumors located in bladder diverticula

Contact & Investigator

Central Contact

Study Coordinator, Department of Urology

✉ postmottak@ous-hf.no

📞 +47 22 89 40 00

Principal Investigator

Andreas Habberstad, MD, PhD

PRINCIPAL INVESTIGATOR

Oslo University Hospital

Frequently Asked Questions

Who can join the NCT07602010 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07602010 currently recruiting?

Yes, NCT07602010 is actively recruiting participants. Contact the research team at postmottak@ous-hf.no for enrollment information.

Where is the NCT07602010 trial being conducted?

This trial is being conducted at Oslo, Norway.

Who is sponsoring the NCT07602010 clinical trial?

NCT07602010 is sponsored by Oslo University Hospital. The principal investigator is Andreas Habberstad, MD, PhD at Oslo University Hospital. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology